Drug intelligence / Profile preview

TSA-T

Development stage: Phase 1
Lead developer: Children's National Hospital
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intracerebroventricular

Overview

TSA-T is an autologous, multi-tumor antigen-specific cytotoxic T lymphocyte (CTL) therapy developed for the treatment of pediatric brain tumors. The therapy involves the generation of T cells directed against personalized tumor-specific antigens (TSAs) that are identified through proteogenomic analysis of a patient's own tumor tissue. By targeting multiple patient-specific neoantigens, TSA-T aims to provide a precise immune response against heterogeneous embryonal central nervous system (CNS) malignancies, including medulloblastoma and atypical teratoid/rhabdoid tumors (ATRT). The cells are manufactured in a specialized GMP facility and administered directly into the cerebrospinal fluid via an intracerebroventricular (ICV) reservoir to bypass the blood-brain barrier and maximize local therapeutic effect.

Other names: multi-tumor antigen specific cytotoxic T lymphocytespersonalized tumor-specific antigen-targeted T cells

Targets

Catenin beta-1 (CTNNB1) S37F neoantigen peptide presented by human leukocyte antigen (HLA)

Beyond the preview

Go deeper on TSA-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSA-T.

Explore the full profile